Peter G. M. Mol

3.0k citations

116 papers · 1.9k indexed · h-index 25

Impact in

Toxicology top 0.2%
- Pharmacovigilance and Adverse Drug Reactions
Geriatrics and Gerontology top 0.5%
- Pharmaceutical Practices and Patient Outcomes

Papers in

Toxicology 27
- Pharmacovigilance and Adverse Drug Reactions 27
Family Practice 12
- Medication Adherence and Compliance 10

Co-authors: Flora M. Haaijer‐Ruskamp Sieta T. de Vries Sabine M. J. M. Straus Patricia M. L. A. van den Bemt Petra Denig Jos G. W. Kosterink Jasperien E. van Doormaal Pieter A. de Graeff
Journals: Drug Safety (29 papers)Clinical Pharmacology & Therapeutics (8 papers)Pharmacoepidemiology and Drug Safety (7 papers)British Journal of Clinical Pharmacology (6 papers)Drug Discovery Today (4 papers)
Partner nations: Netherlands Italy United States

In The Last Decade

Peter G. M. Mol

110 papers receiving 1.8k citations

Peers

Countries citing papers authored by Peter G. M. Mol

Since Specialization

Citations

This map shows the geographic impact of Peter G. M. Mol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter G. M. Mol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter G. M. Mol more than expected).

Fields of papers citing papers by Peter G. M. Mol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter G. M. Mol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter G. M. Mol. The network helps show where Peter G. M. Mol may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter G. M. Mol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter G. M. Mol Line = papers co-authored together Peter G. M. Mol links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions The Lancet Oncology ·Francesco Pignatti, Peter G. M. Mol, Chantal Quinten, Douwe Postmus, Anja Schiel, Maxime Sasseville, Shun Tezuka, Vishal Bhatnagar, Paul G. Kluetz	2025	0
2	Biomarkers for neurodegenerative diseases in regulatory decision‐making by the European Medicines Agency Alzheimer s & Dementia Translational Research & Clinical Interventions ·Audrey Hermans, Elisabeth Bakker, Viktoriia Starokozhko, Loes den Otter, André Elferink, Angela C. Bradshaw, Lorenzo Guizzaro, Peter G. M. Mol, Anna M.G. Pasmooij	2025	1
3	Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic Review Pharmacoepidemiology and Drug Safety ·Esther de Vries, Petra Denig, Taco B. M. Monster, Peter G. M. Mol	2025	0
4	The European Medicines Agency's review of elexacaftor/tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I CFTR variants European Respiratory Journal ·Catherine Drai, Hanneke J van der Woude, Anne J. Lexmond, Tineke van den Hoorn, Peter G. M. Mol, Finbarr P. Leacy, Agnieszka Przybyszewska, Bruno Sepodes, Thomas Castelnovo	2025	0
5	Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction Circulation ·Christian Basile, Felix Lindberg, Lina Benson, Federica Guidetti, Ulf Dahlström, Massimo Piepoli, Peter G. M. Mol, R Scorza, Aldo P. Maggioni, Lars H. Lund, Gianluigi Savarese	2025	7
6	Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy Health Research Policy and Systems ·Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter G. M. Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch	2024	7
7	Real‐World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases Clinical Pharmacology & Therapeutics ·Stefanie Prilla, Sophie Groeneveld, Alexandra Păcurariu, María Clara Restrepo–Méndez, Patrice Verpillat, Carla Torre, Christian Gärtner, Peter G. M. Mol, Frauke Naumann‐Winter, Kieran C. Breen, Nathalie Gault, Liana Martirosyan, Sylvie Benchetrit, Brian Aylward, Violeta Stoyanova‐Beninska, Maura O'Donovan, Sabine M. J. M. Straus, Jesper Kjær, Peter Arlett	2024	7
8	Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials Diabetologia ·Sieta T. de Vries, Michelle J. Pena, Sok Cin Tye, Sanne A. E. Peters, Daniël H. van Raalte, Clare Arnott, Adriaan A. Voors, Peter G. M. Mol, Petra Denig, Hiddo J.L. Heerspink	2024	2
9	A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model PLoS ONE ·Erik Bergman, Anna M.G. Pasmooij, Peter G. M. Mol, Gabriel Westman	2023	2
10	Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry European Heart Journal - Cardiovascular Pharmacotherapy ·Peter Moritz Becher, Gianluigi Savarese, Lina Benson, Ulf Dahlström, Patric Karlström, Peter G. M. Mol, Marco Metra, Deepak L. Bhatt, Bertram Pitt, Lars H. Lund	2023	4
11	Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross‐Sectional Analysis of Centralized Procedures in the European Union 2010–2020 Clinical Pharmacology & Therapeutics ·Katerina M. Mantila, Anna M.G. Pasmooij, Christine E. Hallgreen, Peter G. M. Mol, Job F. M. van Boven	2022	9
12	How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments? Health Economics Review ·Elaine Julian, Fabrizio Gianfrate, Oriol Solà-Morales, Peter G. M. Mol, Jean‐François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Jörg Ruof	2022	17
13	Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy Health Economics Review ·Elaine Julian, Mira Pavlovic, Oriol Solà-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, Wolfgang Greiner, Peter G. M. Mol, Jean‐François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Antonella Cardone, Jörg Ruof	2022	7
14	Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands Drug Safety ·Esther de Vries, Elisabeth Bakker, Taco B. M. Monster, Petra Denig, Peter G. M. Mol	2022	1
15	Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency Frontiers in Medicine ·Marieke J. H. J. Dekker, Sieta T. de Vries, Carolien Versantvoort, Ellen G. E. Drost-van Velze, Mansi Bhatt, Peter J.K. van Meer, Ineke K. Havinga, Christine C. Gispen‐de Wied, Peter G. M. Mol	2021	14
16	Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap Drug Discovery Today ·Viktoriia Starokozhko, Marko J. Kallio, Åsa Kumlin Howell, Anna Mäkinen Salmi, Gunilla Andrew-Nielsen, Mark Goldammer, Manja Burggraf, Wiebke Löbker, Anne C. Böhmer, Eleonora Agricola, Corinne S de Vries, Anna M.G. Pasmooij, Peter G. M. Mol	2020	21
17	Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment Frontiers in Pharmacology ·Rianne A. Weersink, L Timmermans, Margje H. Monster‐Simons, Peter G. M. Mol, Herold J. Metselaar, Sander D. Borgsteede, Katja Taxis	2019	17
18	Impact of Safety-Related Regulatory Action on Clinical Practice Drug Safety ·Sigrid Piening, Flora M. Haaijer‐Ruskamp, Jonie T. N. de Vries, Menno E. van der Elst, Pieter A. de Graeff, Sabine M. J. M. Straus, Peter G. M. Mol	2012	77
19	Prescribing of Rosiglitazone and Pioglitazone Following Safety Signals Drug Safety ·Rikje Ruiter, Loes E. Visser, Myrthe P. P. van Herk‐Sukel, Petronella Geelhoed-Duijvestijn, Sandra de Bie, Sabine M. J. M. Straus, Peter G. M. Mol, Silvana Romio, Ron M. C. Herings, Bruno H. Stricker	2012	33
20	Linkages between glucosaminoglycan and glucan determine alkali-insolubility of the glucan in walls of Saccharomyces cerevisiae FEMS Microbiology Letters ·Peter G. M. Mol	1987	2

About Peter G. M. Mol

Peter G. M. Mol is a scholar working on Toxicology, Family Practice, Geriatrics and Gerontology, Applied Microbiology and Biotechnology and Emergency Medical Services, having authored 116 papers that have together received 1.9k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (35 papers), Pharmaceutical studies and practices (28 papers), Pharmacovigilance and Adverse Drug Reactions (27 papers), Pharmaceutical Practices and Patient Outcomes (21 papers), Pharmaceutical Economics and Policy (16 papers), Patient Safety and Medication Errors (13 papers), Pharmaceutical industry and healthcare (10 papers) and Medication Adherence and Compliance (10 papers). The work is most often cited by research in Toxicology (450 citations), Geriatrics and Gerontology (419 citations), Applied Microbiology and Biotechnology (133 citations), Family Practice (107 citations) and Health Information Management (167 citations). Peter G. M. Mol has collaborated with scholars based in Netherlands, Italy and United States. Frequent co-authors include Flora M. Haaijer‐Ruskamp, Sieta T. de Vries, Sabine M. J. M. Straus, Patricia M. L. A. van den Bemt, Petra Denig, Jos G. W. Kosterink, Jasperien E. van Doormaal, Pieter A. de Graeff, Rianne J. Zaal and Toine C. G. Egberts. Their work appears in journals such as Drug Safety, Clinical Pharmacology & Therapeutics, Pharmacoepidemiology and Drug Safety, British Journal of Clinical Pharmacology and Drug Discovery Today.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact